Clinical Trial Update: Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) [Phase 3]

View source ↗

Summary

Phase 3 MK-0518-292 evaluated the safety and efficacy of reformulated raltegravir 1200 mg once daily in combination with TRUVADA in treatment-naive HIV-1–infect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)
• TRUVADA (EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infection | Phase 3 | Status: COMPLETED | Results posted: 2016-10-31